A Phase 1 Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma

Full Title

A Phase I Study of MB-CART19.1 Cellular Therapy for Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL) Using On-Site Manufacturing with the CliniMACS Prodigy Device

Purpose

Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.

MB-CART19.1 is a cellular therapy made from your own white blood cells (called T cells). We will collect some of your T cells and modify them in a lab to recognize and destroy cancer cells. Then we will give them back to you. These modified T cells are called chimeric antigen receptor (CAR) T cells. Treatments made from them are called CAR T-cell therapies.

Before you get MB-CART19.1, you will have chemotherapy with fludarabine and cyclophosphamide to briefly weaken your immune system. This chemotherapy will help prepare your body for MB-CART19.1. The treatments in this study are given intravenously (by vein).

Contact

For more information and to see if you can join this study, please call Dr. Christian Grommes’ office at 212-610-0344.